Survival Analysis of Patients with Luminal and Non-Luminal Subtype Breast Cancer Receiving Vinorelbine Therapy at Sanglah General Hospital, Denpasar, Bali

Dewa Putu Satria Juristiasa, Putu Anda Tusta Adiputra, Dewa Made Sukrama

Abstract


Introduction: Breast cancer is the most common type and lethal cancer affecting women. Meanwhile, vinorelbine is one of the chemotherapy agents used for luminal and non-luminal breast cancer. Therefore, this study aims to determine the survival difference between patients with luminal and non-luminal subtype breast cancer treated with vinorelbine.

Methods: This study was a retrospective cohort. Women with breast cancer treated with vinorelbine were classified based on estrogen receptor (ER), progesteron receptor (PR), human epidermal growth factor receptor-2 (HER-2) markers, and subtypes. The subjects were followed up to chemotherapy visits with vinorelbine recorded in the medical record. The survival analysis between subtypes was analyzed by the Kaplan-Meier curve.

Results: : One hundred women were obtained with a mean age of 52.36 ± 10.45 years. Based on immunohistochemistry, 60% were ER-positive, 53% were PR positive, and 57% were HER-2- positive. Based on the subtype, 67% were luminal, while 33% were non-luminal. All subjects had a mean survival duration of 155.38 days (95% CI 128.05-182.71). The stratified survival analysis showed a significant difference in survival duration based on HER-2 marker and subtype. The subjects with HER-2 positive survived longer with a mean of 203.37 days (190.72–216.02) than those with HER-2 negative with a mean of 90.10 days (65.68-114.53) (p<0.001). In addition, the subjects with the luminal subtype survived longer with a mean of 174.84 (142.72-206.94) than those with non-luminal with a mean of 90.10 (65.68-114.53) (p = 0.04).

Conclusion: There was a significant difference in survival duration between women with breast cancer treated with vinorelbine chemotherapy who were HER-2 positive, HER-2 negative, and luminal and non-luminal subtypes.

Keywords


breast cancer, immunohistochemical markers, survival, vinorelbine

References


Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

International Agency for Research on Cancer (IARC). Indonesia[Internet]. 2018 [cited 2020 May 26]. Availlable from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf pada 26 Mei 2020.

Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220.

American Cancer Society. Breast Cancer Treatment Guidelines for Patient [Internet]. 2016 [cited 2020 May 26]. Available from https://screening.iarc.fr/doc/Breast_VIII.pdf pada 26 Mei 2020.

Cybulska-Stopa B, Ziobro M, Skoczek M, et al. Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer. Wspolczesna Onkol. 2013;17(1):78–82.

Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. C Open. 2017;5(3):E734–9.

Claessens AKM, Ibragimova KIE, Geurts SME, et al. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Crit Rev Oncol Hematol. 2020;153(May):102988.

Abotaleb M, Kubatka P, Caprnda M, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomed Pharmacother. 2018;101(February):458–77.

Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–57.

Ellard, S. BCCA Protocol Summary for Palliative Therapy for Metastatic Breas Cancer using Vinorelbine [Internet]. 2011 [cited 2020 Jun 2]. Available from: http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Breast/BRAVNAV_Protocol.pdf pada 2 Juni 2020.

Eng LG, Dawood S, Sopik V, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016;160(1):145–52.

Stravodimou A, Zaman K, Voutsadakis IA. Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series. ISRN Oncol. 2014;2014:1–7.

Hussein O, Mosbah M, Farouk O, et al. Hormone receptors and age distribution in breast cancer patients at a university hospital in northern Egypt. Breast Cancer Basic Clin Res. 2013;7(1):51–7.

Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. Ann Med Surg. 2020;49(October 2019):44–8.

Wiguna N, Manuaba I. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di rsup sanglah periode 2003-2012. E-Jurnal Med Udayana. 2012;147:1–13.

Van Uden DJP, Van Maaren MC, Strobbe LJA, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res. 2019;21(1):1–9.

Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;2012(4):CD006243.

Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.


Full Text: PDF

DOI: 10.33371/ijoc.v16i2.899

Article Metrics

Abstract view : 44 times
PDF - 31 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.